Evidence map›Paper›PMID 33778182›Full record

ArticleGene reports2021

Comparative analysis of mutational hotspots in the spike protein of SARS-CoV-2 isolates from different geographic origins.

Sanghoo Lee, Mi-Kyeong Lee, Hyeongkyun Na, Jinwoo Ahn, Gayeon Hong, Youngkee Lee, Jimyeong Park, Yejin Kim, Yun-Tae Kim, Chang-Ki Kim and 2 more

Open access · greenAbstract read
In one paragraph

Article in Gene reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Sanghoo LeeCenter for Companion Biomarker, Seoul Clinical Laboratories (SCL) Healthcare Inc., Republic of Korea.
Mi-Kyeong LeeDepartment of Molecular Diagnostics, Seoul Clinical Laboratories, Republic of Korea.
Hyeongkyun NaCenter for Companion Biomarker, Seoul Clinical Laboratories (SCL) Healthcare Inc., Republic of Korea.
Jinwoo AhnCenter for Companion Biomarker, Seoul Clinical Laboratories (SCL) Healthcare Inc., Republic of Korea.
Gayeon HongCenter for Companion Biomarker, Seoul Clinical Laboratories (SCL) Healthcare Inc., Republic of Korea.
Youngkee LeeCenter for Companion Biomarker, Seoul Clinical Laboratories (SCL) Healthcare Inc., Republic of Korea.
Jimyeong ParkCenter for Companion Biomarker, Seoul Clinical Laboratories (SCL) Healthcare Inc., Republic of Korea.
Yejin KimCenter for Companion Biomarker, Seoul Clinical Laboratories (SCL) Healthcare Inc., Republic of Korea.
Yun-Tae KimCenter for Technology Innovation, Seoul Clinical Laboratories, Republic of Korea.
Chang-Ki KimCenter for Clinical Trial, Seoul Clinical Laboratories, Republic of Korea.
Hwan-Sub LimDepartment of Molecular Diagnostics, Seoul Clinical Laboratories, Republic of Korea.
Kyoung-Ryul LeeCenter for Companion Biomarker, Seoul Clinical Laboratories (SCL) Healthcare Inc., Republic of Korea.
Seoul Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The spike (S) protein mutations of SARS-CoV-2 are of major concern in terms of viral transmission and pathogenesis. Hence, we developed a PCR-based method to rapidly detect the 6 mutational hotspots (H49Y, G476S, V483A, H519Q, A520S, and D614G) in the S protein and applied this method to analyze the hotspots in the viral isolates from different geographical origins. Here, we identified that there was only the D614G mutation in the viral isolates. As of September 30, 2020, the analysis of 113,381 sequences available from the public repositories revealed that the SARS-CoV-2 variant carrying G614 has become the most prevalent form globally. Our results support recent epidemiological and genomic data demonstrating that the viral infectivity and transmission are enhanced by the S protein D614G mutation.

Indexed as

ACE2, angiotensin-converting enzyme-2COVID-19, Coronavirus diseaseCT, cycle thresholdD614G mutationDifferent geographic originsE, envelopeM, membraneMutational hotspotsNGS, next-generation sequencingN, nucleocapsidNsp3, nonstructural proteinOrf, open reading frameRDB, receptor-binding domainRdRp, RNA-dependent RNA polymeraseRT-qPCR, reverse transcriptase-quantitative polymerase chain reactionSARS-CoV-2SARS-CoV-2, severe acute respiratory syndrome coronavirus 2Spike geneSpike proteinS, SpikeTMPRSS2, transmembrane serine protease2

Identifiers

PMID33778182
PMCPMC7985685
OpenAlexW3136740547

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.